Disease-modifying therapies
Health status decline in α-1 antitrypsin deficiency: a feasible outcome for disease modifying therapies?
... of disease modifying therapies in AATD where placebo arms should achieve similar ...of disease modifying therapies expand to this patient ...
9
Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001–2010
... Disease-modifying therapies (DMT) in conjunction with usual symptomatic and supportive care are the primary treatments for MS. Currently available DMTs include glatiramer acetate (GA; Copaxone, Teva ...
8
Comment on 2018 American Academy of Neurology guidelines on disease-modifying therapies in MS
... of disease-modifying therapies (DMTs) in multiple sclerosis (MS) for the first time since ...breakthrough disease requiring change in therapy, de- velopment of better and universally accepted ...
8
The effect of disease modifying therapies on disability progression in multiple sclerosis: A systematic overview of meta analyses
... Disease modifying therapies (DMT) that modulate, modify, or suppress the immune system are a medication class used to treat people living with multiple sclerosis (MS) (see Supplementary Table 1 for a ...
25
Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology
... lists disease-modifying therapies (DMTs) by annualized relapse rate (ARR) reductions from highest to lowest; figure 3 lists DMTs by relative risk of in-study disability progression at 2 ...
7
<p>Managing Disease-Modifying Therapies and Breakthrough Activity in Multiple Sclerosis Patients During the COVID-19 Pandemic: Toward an Optimized Approach</p>
... coronavirus disease 2019 (COVID-19) pandemic has become a major public health challenge of global concern since December 2019, when the virus was recognized in Wuhan, the capital city of Hubei province in China ...
12
The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study
... 4 disease-modifying therapies (DMTs) for at least 2 years prior to enrollment: IM IFN b -1a (Avo- nex ® ), SC IFN b -1b (Betaseron ® /Betaferon ® ), SC IFN b - 1a (Rebif ® ), or SC GA (Copaxone ® ...
7
Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosisReport of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology
... summary: Disease-modifying therapies for adults with multiple sclerosis,” Rae-Grant et ...stopping disease-modifying therapies for clinically isolated syndrome, relapsing- ...
19
Cost of disease-modifying therapies for multiple sclerosisAbout multiple sclerosis
... WHAT ARE MS “ DISEASE-MODIFYING THERAPIES ” ? DMTs are drugs that alter the natural course of MS. They reduce the frequency and severity of attacks, reduce new brain lesions, and slow the development ...
6
The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
... dromal disease and early dementia but, over time, the profile of patients would also include preclinical and early prodromal ...Alzheimer’s disease may not be feasible or ...Alzheimer’s disease to a ...
7
Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis
... Purpose: To evaluate adherence to disease-modifying therapies (DMTs) among patients with multiple sclerosis (MS) initiating oral and injectable DMTs, and to estimate the impact of adh[r] ...
10
Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis
... onset or diagnosis of MS, which could provide insight into the progression and severity of patients’ MS. We measured some proxies of MS severity, such as baseline corticosteroid use, but we did not have access to other ...
12
Effects of disease modifying therapies on brain and grey matter atrophy in relapsing remitting multiple sclerosis
... In the two Phase III studies FREEDOMS and FREE- DOMS II [106, 107], fingolimod was found to reduce the PBV loss in RRMS patients by 36% (p < 0.001) and 33% (p = 0.0002), respectively. Whether this effect on PBV was ...
10
Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosisReport of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology
... detected disease activity and MS relapse within 6 months of discontinuation, with some people with MS having an in- crease in disease activity above their baseline activity, referred to as rebound ...
14
Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment
... Results: A total of 125 patients were included in the final analysis (62.9% female, mean age 44.5 years, 71.5% with relapsing-remitting MS diagnosis). The most important factor for patients was the possibility of ...
12
Adherence to disease-modifying therapies in patients with multiple sclerosis
... Purpose: The main purpose of this study was to examine adherence to first-line disease- modifying therapy (DMT) in MS patients using the self-report Multiple Sclerosis Trea[r] ...
10
Disease-modifying therapies in relapsing–remitting multiple sclerosis
... It has been hypothesized that the efficacy of IFN could be higher if it is used at the first appearance of symptoms, in Clinically Isolated Syndromes suggestive of demyelinating events, a pathology which carries a high ...
9
Persistence to disease-modifying therapies for multiple sclerosis in a Canadian cohort
... a large, population-based cohort of individuals with MS. However, there are still limitations that should be consid- ered. Inherent in all observational studies is the lack of clinical information which could influence ...
9
Patient perspectives on switching disease-modifying therapies in the NARCOMS registry
... We summarized categorical variables using frequency (percent) and continuous variables using mean (standard deviation) or median (interquartile range [IQR]) as appro- priate. Missing responses were not imputed. ...
9
Psychosocial predictors of patient adherence to disease-modifying therapies for multiple sclerosis
... MS disease duration, PHQ-9, GAD-7, comorbidities (yes/no), ECR16-Anx, ECR16-Avoid, family history of MS, belief that MS is associated with nervous psychological disorder (yes/no), belief that MS is associated with ...
6